Very quick highlights from the Aveo Pharma $AVEO 2q-2012 conference call (Transcript via SeekingAlpha.)
- tivozanib NDA 3q-2012 or maybe slip into 4q-2012
- will collect final OS data 2 years afer last patient enrolled - data sweep in 3q-2012, will include in 120-day question response to EMA
- additional survival analysis will not be at ESMO.
- 1 year Overall Survival (OS) of 81 vs 77% not in favor of tivozanib. But 53% of control patients vs 17% received additional therapy (many crossed over to tivo)
- ficlatuzumab data at ESMO and info on further development plans (missed primary endpoint)
- AV-203 - ERBB3 inhibitor started phase 1 clinical trial in 2012
- year-end 2012 cash $120m [I can't understand their enormous burn rate], enough to last into 2h-2013
RSS Feed
